Последние исследования

EudraCT Number: 2022-002954-25

Sponsor Protocol Number: ASND0036

Start Date:

Sponsor Name: Ascendis Pharma Growth Disorders A/S

Full Title: ApproaCH: A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial evaluating Efficacy and Safety of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in C...

Medical condition: Achondroplasia (ACH) in prepubertal children

Disease:	Version	SOC Term	Classification Code	Term	Level
	25.0	100000004850	10000452	Achondroplasia	LLT

Population Age: Children, Under 18

Gender: Male, Female

Trial protocol: IE (Ongoing) DK (Ongoing)

Trial results: (No results available)

EudraCT Number: 2021-005478-24

Sponsor Protocol Number: DYNE251-DMD-201

Start Date:

Sponsor Name: Dyne Therapeutics, Inc

Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics of DYNE-251 Administered to Participan...

Medical condition: Duchenne Muscular Dystrophy

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10010331 - Congenital, familial and genetic disorders	10013801	Duchenne muscular dystrophy	PT

Population Age: Children, Adolescents, Under 18

Gender: Male

Trial protocol: IE (Ongoing) BE (Ongoing) ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2017-002961-23

Sponsor Protocol Number: ODO-TE-B301

Start Date:

Sponsor Name: Odonate Therapeutics, Inc.

Full Title: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally...

Medical condition: Patients with Breast Cancer

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: CZ (Prematurely Ended) HU (Completed) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) DE (Completed) BE (Prematurely Ended) FR (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2008-000640-14

Sponsor Protocol Number: 1245.9

Start Date:

Sponsor Name: Boehringer ingelheim Pharma GmbH & Co KG

Full Title: A Phase IIb, randomized, parallel group safety, efficacy, and pharmacokinetics study of BI 10773 (5mg, 10mg and 25mg) administered orally once daily over 12 weeks compared double blind to placebo, ...

Medical condition: Type 2 Diabetes mellitus

Disease:	Version	SOC Term	Classification Code	Term	Level
	9.1		10045242	Type II diabetes mellitus	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) SE (Completed) IT (Completed) EE (Completed) LT (Completed) SK (Completed)

Trial results: View results

EudraCT Number: 2022-002367-29

Sponsor Protocol Number: ITM202203

Start Date:

Sponsor Name: Instituut van Tropische Geneeskunde Antwerpen

Full Title: A two-centre open-label non-inferiority trial to assess the immunogenicity and safety of an intradermal and an intramuscular single-visit dosing regimen of purified chick-embryo cell-culture rabies...

Medical condition: Rabies is a viral infection that affects the central nervous system. It causes encephalitis which is almost invariably fatal. Preventive vaccination alone implies no complete protection, but simpli...

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10021881 - Infections and infestations	10037742	Rabies	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: BE (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2018-000261-36

Sponsor Protocol Number: HTA-HG5-02

Start Date:

Sponsor Name: HOLOSTEM TERAPIE AVANZATE S.R.L.

Full Title: MULTICENTRE, OPEN-LABEL, UNCONTROLLED, PIVOTAL CLINICAL TRIAL TO CONFIRM THE EFFICACY AND SAFETY OF AUTOLOGOUS FIBRIN-CULTURED EPIDERMAL GRAFTS CONTAINING EPIDERMAL STEM CELLS GENETICALLY MODIFIED ...

Medical condition: Inherited Epidermolysis Bullosa (EB) is a group of rare, devastating genetic disorders characterized by structural and mechanical fragility of skin and mucosal membranes, impairing the patient's qu...

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10010331 - Congenital, familial and genetic disorders	10014989	Epidermolysis bullosa	PT

Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: IT (Ongoing)

Trial results: (No results available)

EudraCT Number: 2013-002896-17

Sponsor Protocol Number: V1.17.05.2013

Start Date:

Sponsor Name: Orthopädisches Spital Speising

Full Title: Functional evaluation of two therapy concepts: dynamic orthoses and BoNT

Medical condition: Infantile cerebral palsy

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Children, Under 18

Gender: Male, Female

Trial protocol: AT (Completed)

Trial results: (No results available)

EudraCT Number: 2009-012667-34

Sponsor Protocol Number: BRONCHIOLITIS

Start Date:

Sponsor Name: Oslo University Hospital - Ullevål

Full Title: BRONCHIOLITIS, OPTIMAL TREATMENT IN INFANTS AND PROGNOSIS

Medical condition: Acute bronchiolitis

Disease:	Version	SOC Term	Classification Code	Term	Level
	12.0		10000686	Acute bronchiolitis	LLT

Population Age: Newborns, Infants and toddlers, Under 18

Gender: Male, Female

Trial protocol: NO (Ongoing)

Trial results: (No results available)

EudraCT Number: 2006-006816-31

Sponsor Protocol Number: P060104

Start Date:

Sponsor Name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)

Full Title: Effet du mazindol sur le Trouble Déficit de l'Attention/Hyperactivité chez l'enfant : étude prospective pilote (phase II) d'efficacité, de tolérance et de pharmacocinétique

Medical condition: Enfants de 6 à 12 ans présentant un TDAH et suivi dans le Service de Psychopathologie de l'Enfant et de l'Adolescent de l'Hôpital Robert Debré

Disease:	Version	SOC Term	Classification Code	Term	Level
	8.1		10003736	Trouble Déficit de l'Attention/Hyperactivité	PT

Population Age: Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: FR (Ongoing)

Trial results: (No results available)

EudraCT Number: 2021-004039-10

Sponsor Protocol Number: NL78130.041.21

Start Date:

Sponsor Name: UMC Utrecht - Van Creveldkliniek

Full Title: Pharmacokinetic-guided dosing of emicizumab in congenital haemophilia A patients – The DosEmi study

Medical condition: Congenital hemophilia A

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000004850	10060612	Hemophilia A	LLT

Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly

Gender: Male

Trial protocol: NL (Ongoing)

Trial results: (No results available)

Последние исследования

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства